|
IAC Express 2010 |
| Issue number 882: August 16, 2010 |
|
|
Please click here to subscribe to IAC Express
as well as other FREE IAC periodicals. |
|
Contents
of this Issue
Select a title to jump to the article. |
- New: CDC
issues VISs for the two 2010-11 influenza vaccines--available in English
only
- MMWR
publishes ACIP's recommendations for use of CSL's influenza vaccine during
2010-11
- IAC
updates four handouts, including its vaccine administration record forms,
influenza vaccine products chart, and declination of influenza vaccination
form
- IAC
updates online "Ask The Experts" Q&A sections related to PCV and PPSV
- IAC's
Video of the Week features children promoting the importance of the
hepatitis B birth dose
- Register
for CDC's September 2 Net Conference on ACIP'S influenza recommendations
and CDC's communication plans
- "CDC
Features" educates parents about getting their children vaccinated in time
for school
- MMWR
issues erratum for ACIP's 2010 influenza recommendations
-
Conference on the Science, Ethics, and Politics of Vaccine Mandates
scheduled for September 21 in Philadelphia
- WHO
issues position paper on rabies vaccine
- MMWR
publishes report on laboratory containment of wild poliovirus in WHO's
Region of the Americas
|
| |
| Abbreviations |
|
|
AAFP, American Academy of Family Physicians; AAP,
American Academy of Pediatrics; ACIP, Advisory Committee on Immunization
Practices; AMA, American Medical Association; CDC, Centers for Disease
Control and Prevention; FDA, Food and Drug Administration; IAC, Immunization
Action Coalition; MMWR, Morbidity and Mortality Weekly Report; NCIRD,
National Center for Immunization and Respiratory Diseases; NIVS, National
Influenza Vaccine Summit; VIS, Vaccine Information Statement; VPD,
vaccine-preventable disease; WHO, World Health Organization. |
| |
|
Issue 882: August 16, 2010 |
|
|
|
1. |
New: CDC issues VISs for the two 2010-11 influenza vaccines--available in
English only
On August 10, CDC issued two new interim VISs for
influenza
vaccine. One is for for trivalent inactivated influenza
vaccine (TIV; injectable), the other for live attenuated
intranasal influenza vaccine (LAIV; nasal spray). The new
VISs are intended for use during the 2010-11 influenza
vaccination season. They replace both 2009-10 seasonal
influenza vaccine VISs, which were dated 8/11/09.
Page 2 of the 8/10/10 interim VIS for injectable influenza
vaccine includes a box with this information for patients:"One brand of inactivated flu vaccine, called Afluria, should
not be given to children 8 years of age or younger, except
in special circumstances. A related vaccine was associated
with fevers and fever-related seizures in young children in
Australia. Ask your healthcare provider for more
information."
To access the 8/10/10 interim VIS for injectable influenza
vaccine, go to: http://www.immunize.org/vis/vis_flu_inactive.asp
To access the 8/10/10 interim VIS for nasal-spray influenza
vaccine, go to: http://www.immunize.org/vis/vis_flu_live.asp
Translations will be available in the weeks to come.
For information about the use of VISs, and for VISs in more
than 35 languages, visit IAC's VIS web section at
http://www.immunize.org/vis
For general information about VISs from CDC's website go to:
http://www.cdc.gov/vaccines/pubs/vis
Back to top |
| |
|
|
2. |
MMWR publishes ACIP's recommendations for use of CSL's influenza vaccine
during 2010-11
CDC published "Update: Recommendations of the
Advisory
Committee on Immunization Practices (ACIP) Regarding Use of
CSL Seasonal Influenza Vaccine (Afluria) in the United
States During 2010-11" in the August 13 issue of MMWR. The
first paragraph is reprinted below.
During the 2010 influenza season in Australia,
administration of a 2010 Southern Hemisphere seasonal
influenza trivalent inactivated vaccine (TIV) (Fluvax Junior
and Fluvax) manufactured by CSL Biotherapies was associated
with increased frequency of fever and febrile seizures in
children aged 6 months through 4 years. Postmarketing
surveillance indicated increased reports of fever in
children aged 5-8 years after vaccination with Fluvax
compared to previous seasons. An antigenically equivalent
2010-11 Northern Hemisphere seasonal influenza TIV (Afluria)
manufactured by CSL Biotherapies is approved by the Food and
Drug Administration (FDA) for persons aged >=6 months in the
United States. Prescribing information for the 2010-11
Afluria formulation includes a warning that "Administration
of CSL's Southern Hemisphere influenza vaccine has been
associated with increased postmarketing reports of fever and
febrile seizures in children predominantly below the age of
5 years as compared to previous years." In the United
States, annual influenza vaccination is recommended for all
persons aged >=6 months. On August 5, 2010, the Advisory
Committee on Immunization Practices (ACIP) recommended that
the 2010-11 Afluria vaccine not be administered to children
aged 6 months through 8 years. Other age-appropriate,
licensed seasonal influenza vaccine formulations should be
used for prevention of influenza in these children. If no
other age-appropriate, licensed inactivated seasonal
influenza vaccine is available for a child aged 5-8 years
who has a medical condition that increases their risk for
influenza complications, Afluria can be used; however,
providers should discuss with the parents or caregivers the
benefits and risks of Afluria use before administering this
vaccine to children aged 5-8 years.
To access the updated recommendations in full, go to
http://www.cdc.gov/mmwr/PDF/wk/mm5931.pdf and see pages 989-992.
Back to top |
| |
|
|
3. |
IAC updates four handouts, including its vaccine administration record forms,
influenza vaccine products chart, and declination of influenza vaccination
form
IAC recently revised the following four handouts
for
healthcare professionals.
(1) IAC updated "Vaccine Administration Record for Children
and Teens," increasing the form from one page to two, adding
a vaccine trade name chart, and including four pages of
examples. Go to: http://www.immunize.org/catg.d/p2022.pdf
(2) IAC updated "Vaccine Administration Record for Adults,"
increasing the form from one page to two, adding a vaccine
trade name chart, and including two pages of examples. Go
to: http://www.immunize.org/catg.d/p2023.pdf
(3) IAC revised "Influenza Vaccine Products for the 2010-11
Influenza Season," updating it to include information on the
products licensed for use 2010-11 and adding instructions
for administering injectable and nasal-spray vaccines. Go
to: http://www.immunize.org/catg.d/p4072.pdf
(4) IAC made minor revisions to "Declination of Influenza
Vaccination." Go to: http://www.immunize.org/catg.d/p4068.pdf
IAC's Handouts for Patients and Staff web section offers
healthcare professionals and the public approximately 250
FREE English-language handouts (many also available in
translation), which we encourage website users to print out,
copy, and distribute widely. To access all of IAC's free
handouts, go to: http://www.immunize.org/handouts
Back to top |
| |
|
|
4. |
IAC updates online "Ask The Experts" Q&A sections related to PCV and PPSV
IAC updated two of its online "Ask the Experts"
Q&A
sections, one about pneumococcal conjugate vaccine and
disease, the other about pneumococcal polysaccharide vaccine
and disease. Vaccination experts at CDC provided input for
updating both sections. IAC's "Ask the Experts" Q&As are
reviewed and updated annually. The process is ongoing; IAC
Express will inform readers as sections are reviewed and
revised.
To access the revised pneumococcal conjugate vaccine and
disease Q&As, go to:
http://www.immunize.org/askexperts/experts_pcv.asp
To access the revised pneumococcal polysaccharide vaccine
and disease Q&As, go to:
http://www.immunize.org/askexperts/experts_ppv.asp
To access the index page of "Ask the Experts" Q&As for all
other vaccines, go to: http://www.immunize.org/askexperts
Back to top |
| |
|
|
5. |
IAC's Video of the Week features children promoting the importance of the
hepatitis B birth dose
Children state the importance of the hepatitis B
vaccination
at birth in this charming 30-second video developed by
HepBMoms. A unique online resource, HepBMoms
(http://www.hepbmoms.org) is intended for pregnant mothers,
perinatal hepatitis B prevention program coordinators,
healthcare providers, and anyone who is concerned about
hepatitis B.
The video will be available on the home page of IAC's
website through August 22. To access it, go to:
http://www.immunize.org and click on the image under the
words Video of the Week. To access the video after August
22, visit http://www.hepbmoms.org
Remember to bookmark IAC's home page to view a new video
every Monday. To view an IAC Video of the Week from the
past, go to the video archive at http://www.immunize.org/votw
Back to top |
| |
|
|
6. |
Register for CDC's September 2 Net Conference on ACIP'S influenza
recommendations and CDC's communication plans
The next NCIRD live Net Conference will cover the
2010
influenza recommendations and CDC's influenza vaccine
communications plans and resources. The Net Conference is
scheduled from noon to 1PM ET on September 2. Cindy
Weinbaum, MD, MPH, will discuss the recommendations;
Kristine Sheedy, PhD, will outline CDC's communications
plans and resources. Andrew Kroger, MD, MPH, will moderate.
Participation in the Q&A section of the program is available
by phone and Internet. This is a limited-entry event. CDC
urges early registration; registration will close on August
31 or when the course is full.
To register, go to: http://www2.cdc.gov/vaccines/ed/ciinc
Back to top |
| |
|
|
7. |
"CDC Features" educates parents about getting their children vaccinated in
time for school
The "CDC Features" web section now includes
information for
parents on the importance of making sure their children's
vaccinations are up to date in time for the start of the
school year.
To access "School Starts Soon--Is Your Child Fully
Vaccinated?" go to:
http://www.cdc.gov/Features/CatchUpImmunizations
To access an alphabetical index of all "CDC Features," go
to: http://www.cdc.gov/features
Back to top |
| |
|
|
8. |
MMWR
issues erratum for ACIP's 2010 influenza recommendations
CDC published " Erratum: Vol. 59, No. RR-8" in
the August 13
issue of MMWR. The erratum is reprinted below. IAC Express
editor's note: You will find a link to the corrected 2010
influenza recommendations at the end of this IAC Express
article.
In the MMWR Recommendations and Reports "Prevention and
Control of Influenza with Vaccines: Recommendations of the
Advisory Committee on Immunization Practices (ACIP), 2010,"
on page 18, the first two sentences under the heading
"Pregnant Women and Neonates" should read, "FDA has
classified FluLaval, Fluarix (GlaxoSmithKline Biologicals),
and Agriflu (Novartis Vaccines and Diagnostics Limited)
influenza vaccines as "Pregnancy Category B" medications,
indicating that animal reproduction studies have not
demonstrated a fetal risk, but there are no controlled
studies in pregnant women; all other influenza vaccines are
classified as Pregnancy Category C" medications, indicating
that adequate animal reproduction studies have not been
conducted. Available data do not indicate that any influenza
vaccine causes fetal harm when administered to a pregnant
woman, and any of the approved TIV formulations may be used
for vaccinating pregnant women."
To access the erratum in web-text (HTML) format, go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5931a6.htm
To access the corrected "Prevention and Control of Influenza
with Vaccines: Recommendations of the Advisory Committee on
Immunization Practices (ACIP), 2010," go to:
http://www.cdc.gov/mmwr/pdf/rr/rr5908.pdf
Back to top |
| |
|
|
9. |
Conference on the Science, Ethics, and Politics of Vaccine Mandates scheduled
for September 21 in Philadelphia
The University of Pennsylvania's Center for
Bioethics will
host a conference on the Science, Ethics, and Politics of
Vaccine Mandates on September 21. Speakers include Arthur
Caplan, PhD, director, Center for Bioethics, and Paul Offit,
MD, chief, Infectious Diseases Section, Children's Hospital
of Philadelphia.
For information on the conference, including the program and
links to readings, go to:
http://www.bioethics.upenn.edu/ConferenceSept21.shtml
IMPORTANT: There is no fee to attend but you MUST register
at bioevmc@mail.med.upenn.edu Or contact Janice Pringle or
Matthew Isensberg, at the Center for Bioethics, (215) 898-7136.
Back to top |
| |
|
|
10. |
WHO issues position paper on rabies vaccine
The August 6 issue of the WHO periodical "Weekly
Epidemiological Record" includes the latest WHO position
paper on rabies vaccine. To access it, go to:
http://www.who.int/wer/2010/wer8532.pdf
A collection of WHO position papers on vaccines is available
in alphabetical order at
http://www.who.int/immunization/documents/positionpapers
They are available in chronological order on the IAC website
at http://www.immunize.org/who
Back to top |
| |
|
|
11. |
MMWR publishes report on laboratory containment of wild poliovirus in WHO's
Region of the Americas
CDC published "Completion of National Laboratory
Inventories
for Wild Poliovirus Containment--Region of the Americas,
March 2010" in the August 13 issue of MMWR. A summary made
available to the press is reprinted below in its entirety.
With progress toward eradication of wild poliovirus
transmission since 1988, the World Health Organization (WHO)
has been assisting member countries in starting the process
leading to laboratory containment of wild poliovirus.
Previously, countries in the European and Western Pacific
regions of WHO completed Phase I of this process, a
comprehensive survey, and an inventory of facilities holding
wild poliovirus or infected samples. Following surveys and
inventories conducted by 43 countries and territories in the
Region of the Americas and voluntary destruction of some
materials, 215 facilities in nine countries of the Americas
(including 180 in the United States) reported retaining wild
poliovirus as of March 2010. Completion of the survey and
inventory in three polio-free WHO regions provides a solid
base for subsequent steps toward final containment once
interruption of wild poliovirus transmission is achieved.
Like smallpox, laboratory containment of wild poliovirus
(and potentially infectious stored samples) in safe
conditions is essential to minimize the risk for
reintroducing wild poliovirus into poliomyelitis-free
communities after eradication. Completion of the first phase
toward laboratory containment in the Americas, Europe, and
Asia is a major advance in preparation of polio eradication.
To access the full article in web-text (HTML) format, go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5931a3.htm
Back to top |
| |
|
|
